MannKind Receives PMDA Clearance for Phase 3 Trial of Clofazimine Inhalation Suspension for NTM Lung Disease
MannKind Corporation has announced clearance from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to begin the Phase 3 clinical trial (ICoN-1) of its Clofazimine Inhalation Suspension for treating nontuberculous...
Read More